P selectins and immunological profiles in HCV and Schistosoma mansoni induced chronic liver disease

• Published in: BMC gastroenterology Vol. 14; no. 1; p. 132
• Main Authors: Kamel, Mahmoud M, Fouad, Shawky A, Basyoni, Maha M A
• Format: Journal Article
• Language: English
• Published: England BioMed Central 28.07.2014; BioMed Central Ltd
• Subjects: Adult; Animals; Antigens; Blood; Blood platelets; Case-Control Studies; Coinfection; Cytokines; Disease prevention; Enzymes; Female; Flow Cytometry; Gastroenterology; Hepacivirus; Hepatitis; Hepatitis C virus; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - immunology; Humans; Infections; Internal medicine; Leukocytes; Ligands; Liver cancer; Liver cirrhosis; Liver Cirrhosis - blood; Liver Cirrhosis - immunology; Liver diseases; Liver Diseases - blood; Liver Diseases - immunology; Lymphocyte Activation - immunology; Lymphocyte Count; Male; Medicine; Middle Aged; P-Selectin - metabolism; Platelet Activation; Platelet Count; Schistosoma mansoni; Schistosomiasis mansoni - blood; Schistosomiasis mansoni - immunology; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Viral infections; Cairo Egypt; Egypt
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/1471-230X-14-132

Hepatitis C virus (HCV) and Schistosoma mansoni are major causes of chronic liver disease (CLD) in which immune alteration is common. Recent studies suggested that certain platelets and lymphocytes activation markers may have an impact on progression of CLD. This study aimed to evaluate the potential of platelets and lymphocytes activation molecules expression on the pathogenesis of CLD in distinct or concomitant chronic HCV and schistosomiasis mansoni infections. The study populations were divided into group-I: patients with chronic schistosomiasis mansoni, group-II: HCV patients without cirrhosis, group-III: patients with combined liver diseases without cirrhosis, group-IV: patients with chronic HCV and liver cirrhosis and group-V: Age and sex matched healthy individuals as normal controls. All groups were subjected to full clinical evaluation, ELISA anti-HCV antibodies screening, parasitological examination for diagnosing S. mansoni and flow cytometry for lymphocyte (CD3, CD4, CD8, CD19, CD22, & CD56) and platelets activation (CD41, CD42 & CD62P (P- selectins)) markers. The platelet count was significantly decreased in HCV and/or S. mansoni patients. The total T-lymphocytes and T-helper cells were significantly reduced, while T-cytotoxics were increased. The patients possessed a significantly higher platelets activation marker; CD62P (P-selectins) and higher mean fluorescent intensity (MFI) positivity. There were considerable correlations between platelets count and both of CD62P and MFI. Our Findings suggest an increased expression of certain platelets and lymphocytes activation markers in chronic HCV and S. mansoni induced CLD that may have a role in disease progression.